Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford Molecular Group PLC

www.oxfordmolecular.com

Latest From Oxford Molecular Group PLC

QuantumBio Inc.

By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.
BioPharmaceutical Platform Technologies

IP2IPO Ltd.

IP2IPO Ltd. aims to facilitate technology transfer from UK universities, securing funding and advice to help commercialize intellectual property (IP).
Europe Deals

Isis Innovation LTD

Oxford University's technology transfer group, Isis Innovation, has been around for thirteen years. But it's only since 1997 that the show has really begun.
BioPharmaceutical

Of Mice and Men: Predictive Toxicology

Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
Clinical Trials Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford Molecular Group PLC
  • Senior Management
  • Tony Marchington, DPhil, Chmn. & CEO
    Derek R Marsh, Fin. Dir.
    Suzanne Mattingly, PhD, VP, Global Mktg.
    Mark Cortelyou, VP, Bioinformatics
    David E Jackson, PhD, COO
  • Contact Info
  • Oxford Molecular Group PLC
    Phone: (44) 1865 784600
    Oxford Science Park
    Medawar Ctr.
    Oxford, OX4 4GA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register